Eisai Co., Ltd. completed a major renovation of its Tsukuba Research Laboratories in Ibaraki, Japan, as part of strategic investment to execute its medium-term business plan, “EWAY Future & Beyond.”

Eisai implements research and development activities under the DHBL (Deep Human Biology Learning) drug discovery and development system in an effort to create new drugs based on innovative and efficient next-generation drug discovery concepts.

According to the company, Tsukuba Research Laboratories is positioned as a core facility in the DHBL drug discovery and development system.

The renovation aims to accelerate knowledge circulation by connecting each researcher with patients, other members within the laboratories, other research sites across the world, and external researchers. Total investment on this major renovation was 8.5 billion yen (~$65mn).

In a statement the company said that in favor of generating natural communication between researchers across different therapeutic areas on a daily basis, workspaces for biology researchers and data scientists are allocated on the same floor, and likewise workspaces for chemistry and pharmacokinetics/analytical researchers are placed on nearby floors to foster new connections and knowledge exchange.

With the renovated laboratories, Eisai says it will accelerate the drug discovery activities under the DHBL drug discovery system in order to fulfill unmet medical needs.